Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience

Abdul Muqtadir Abbasi; Mohammad Usman Shaikh; Natasha Ali; Maria Khan; Salman Muhammad Soomar

doi:10.1016/j.lrr.2022.100295

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience

Abdul Muqtadir Abbasi, Mohammad Usman Shaikh, Natasha Ali, Maria Khan, Salman Muhammad Soomar

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

Original language	English (UK)
Article number	100295
Journal	Leukemia Research Reports
Volume	17
DOIs	https://doi.org/10.1016/j.lrr.2022.100295
Publication status	Published - Jan 2022

Keywords

Complete resposne
Eltrombopag
Immune thrombocytopenia
Platelet response
Severe aplastic anemia

Access to Document

10.1016/j.lrr.2022.100295

Cite this

@article{b5aa634637b64bfcacb3a2841c5ca965,

title = "Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience",

abstract = "Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.",

keywords = "Complete resposne, Eltrombopag, Immune thrombocytopenia, Platelet response, Severe aplastic anemia",

author = "Abbasi, \{Abdul Muqtadir\} and Shaikh, \{Mohammad Usman\} and Natasha Ali and Maria Khan and Soomar, \{Salman Muhammad\}",

note = "Funding Information: Department of Health Information and Management Systems, Aga Khan University Hospital Karachi, Pakistan Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jan,

doi = "10.1016/j.lrr.2022.100295",

language = "English (UK)",

volume = "17",

journal = "Leukemia Research Reports",

issn = "2213-0489",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia

T2 - A single-center experience

AU - Abbasi, Abdul Muqtadir

AU - Shaikh, Mohammad Usman

AU - Ali, Natasha

AU - Khan, Maria

AU - Soomar, Salman Muhammad

PY - 2022/1

Y1 - 2022/1

N2 - Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

AB - Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

KW - Complete resposne

KW - Eltrombopag

KW - Immune thrombocytopenia

KW - Platelet response

KW - Severe aplastic anemia

UR - https://www.scopus.com/pages/publications/85125266414

U2 - 10.1016/j.lrr.2022.100295

DO - 10.1016/j.lrr.2022.100295

M3 - Article

AN - SCOPUS:85125266414

SN - 2213-0489

VL - 17

JO - Leukemia Research Reports

JF - Leukemia Research Reports

M1 - 100295

ER -

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this